Table 2.

Significantly dysregulated miRNAs identified in multiple linear regression analysis of Parkinson's disease versus controls

miRNA upregulated n = 27; downregulated n = 19	Effect size	P-value
miR-145-5p	0.219	2.3e−07**
miR-151a-3p	0.218	8.0e−06**
miR-3677-5p	0.165	1.8e−05**
miR-145-3p	0.069	2.2e−05*
miR-130a-3p	−0.170	2.5e−05*
miR-491-5p	0.108	2.8e−05*
miR-4516	0.177	2.9e−05*
miR-197-3pa	0.180	3.9e−05*
miR-505-3pa	0.160	4.2e−05*
miR-1285-5p	0.090	6.4e−05*
miR-4538	−0.104	6.6e−05*
miR-18b-5p	−0.325	7.2e−05*
miR-539-3p	0.066	7.8e−05*
miR-122-5p	−0.163	8.7e−05*
miR-18a-5p	−0.338	1.2e−04*
miR-103a-3p	−0.116	1.7e−04*
miR-326	0.203	1.7e−04*
miR-3923	−0.084	1.8e−04*
miR-3155a	0.071	1.8e−04*
miR-1225-5pa	0.091	2.0e−04*
miR-937-5p	−0.096	2.4e−04*
miR-3145-5p	0.068	2.6e−04*
miR-125a-5p	0.188	2.7e−04*
miR-6720-5p	0.133	2.8e−04*
miR-451a	−0.018	3.0e−04*
let-7d-3pa	0.150	3.1e−04*
miR-7106-5p	−0.166	3.2e−04*
miR-328-3p	0.168	3.5e−04*
miR-6799-5p	−0.144	4.1e−04*
miR-23a-3p	0.150	4.5e−04*
miR-6770-3p	0.099	4.6e−04*
miR-6849-5p	−0.137	4.6e−04*
miR-4323	0.127	4.7e−04*
miR-762	−0.097	5.1e−04*
miR-590-5p	−0.327	5.2e−04*
miR-138-2-3p	−0.110	5.2e−04*
miR-6716-5p	0.150	5.4e−04*
miR-922	0.188	5.4e−04*
miR-4328	0.056	5.7e−04*
miR-20b-5p	−0.233	6.2e−04*
miR-423-3p	0.129	6.6e−04*
miR-4281	0.103	6.7e−04*
miR-378a-5p	0.175	7.0e−04*
miR-6727-5p	−0.119	8.0e−04*
miR-4513	−0.175	8.4e−04*
miR-662	−0.066	8.9e−04*

Log fold changes and P-values for effect in Parkinson's disease versus controls (model HCvPD_mlr; n = 367 versus 416). No effect implies fold change = 1 and log fold change = 0. Significantly upregulated and downregulated miRNAs are demonstrated by positive and negative effect sizes, respectively.

^aOverlapping miRNAs in significance and direction between Parkinson’s disease versus controls and progressive supranuclear palsy versus controls are highlighted in bold.

^*Significant at an FDR of 5% (Benjamini–Hochberg).

^**Significant at an FWER of 5% (Bonferroni) across all comparisons.